Telsey Advisory Group analyst Dana Telsey reiterates Clear Secure (NYSE:YOU) with a Outperform and maintains $38 price target.
TransCode Therapeutics Announces Preliminary Clinical Results In First Patient In Phase 0 Clinical Study With Lead Therapeutic Candidate, TTX-MC138
TransCode Therapeutics, Inc. (NASDAQ:RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced preliminary results with its lead therapeutic candidate,